drugset / Trial / NCT07276737
Preconditioning With a Combination of Thiotepa, Cyclophosphamide, and Busulfan for Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of NK/T-Cell Lymphoma
Phase 2
Not yet recruiting
37 enrolled
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
NaSingle-groupOpen-labelTreatment
Summary
Evaluation of the efficacy and safety of Thiotepa combined with Cyclophosphamide and Busulfan as conditioning regimen before allo-HSCT for the treatment of NK/T cell lymphoma
Timeline
- Start
- 2025-12-30
- Primary completion
- 2029-12-30
- Completion
- 2029-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Thiotepa | Other / unclassified | 5 mg/kg | — |
| Background | Busulfan | Small molecule | 3.2 mg/kg | — |
| Background | Cyclophosphamide | Other / unclassified | 40 mg/kg | — |
| Background | Cyclophosphamide | Other / unclassified | 50 mg/kg | — |